Analysts Offer Predictions for Korro Bio FY2025 Earnings

Korro Bio, Inc. (NASDAQ:KRRO) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Korro Bio in a research note issued to investors on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the company will post earnings per share of ($8.91) for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share.

A number of other equities research analysts also recently weighed in on KRRO. Royal Bank of Canada lowered their target price on shares of Korro Bio from $105.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 19th. Chardan Capital assumed coverage on shares of Korro Bio in a research report on Wednesday, April 16th. They issued a “buy” rating and a $25.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $115.00 price objective on shares of Korro Bio in a report on Thursday, March 20th. Finally, Oppenheimer began coverage on shares of Korro Bio in a research report on Friday, January 10th. They set an “outperform” rating and a $155.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $114.63.

Korro Bio Stock Up 3.7 %

Korro Bio stock opened at $18.40 on Thursday. The business has a 50-day simple moving average of $18.76 and a 200 day simple moving average of $36.79. Korro Bio has a 52 week low of $11.13 and a 52 week high of $98.00. The stock has a market cap of $172.76 million, a price-to-earnings ratio of -1.96 and a beta of 2.31.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.33) by $0.07. The firm had revenue of $2.27 million during the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its position in shares of Korro Bio by 374.9% during the third quarter. JPMorgan Chase & Co. now owns 12,391 shares of the company’s stock valued at $414,000 after buying an additional 9,782 shares during the period. Rhumbline Advisers boosted its stake in Korro Bio by 7.8% in the 4th quarter. Rhumbline Advisers now owns 9,602 shares of the company’s stock worth $366,000 after purchasing an additional 691 shares in the last quarter. Bank of New York Mellon Corp grew its position in Korro Bio by 3.0% during the 4th quarter. Bank of New York Mellon Corp now owns 14,788 shares of the company’s stock valued at $563,000 after purchasing an additional 435 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Korro Bio during the 4th quarter valued at about $394,000. Finally, AlphaQuest LLC raised its holdings in Korro Bio by 23.2% in the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock worth $83,000 after buying an additional 412 shares during the last quarter. Hedge funds and other institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).